Cargando…
Re-examination of MAGE-A3 as a T-cell Therapeutic Target
In 2013, an innovative MAGE-A3-directed cancer therapeutic of great potential value was terminated in the clinic because of neurotoxicity. The safety problems were hypothesized to originate from off-target T-cell receptor activity against a closely related MAGE-A12 peptide. A combination of publishe...
Autores principales: | Martin, Aaron D., Wang, Xueyin, Sandberg, Mark L., Negri, Kathleen R., Wu, Ming L., Toledo Warshaviak, Dora, Gabrelow, Grant B., McElvain, Michele E., Lee, Bella, Daris, Mark E., Xu, Han, Kamb, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946352/ https://www.ncbi.nlm.nih.gov/pubmed/33284140 http://dx.doi.org/10.1097/CJI.0000000000000348 |
Ejemplares similares
-
Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers
por: Wang, Xueyin, et al.
Publicado: (2021) -
Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity
por: Tokatlian, Talar, et al.
Publicado: (2022) -
Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
por: Tokatlian, Talar, et al.
Publicado: (2022) -
A multivariate, quantitative assay that disentangles key kinetic parameters of primary human T cell function in vitro
por: Huang, Grace L., et al.
Publicado: (2020) -
Suppression of Gq Function Using Intra-Pipette Delivery of shRNA during Extracellular Recording in the Ventral Tegmental Area
por: Nimitvilai, Sudarat, et al.
Publicado: (2013)